Arrowhead Pharmaceuticals Appoints William Waddill to Board of Directors

Home/Newsroom/

Arrowhead Pharmaceuticals Appoints...

PASADENA, Calif.–(BUSINESS WIRE)–

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the

board of directors elected veteran biotechnology executive William

Waddill as an independent director of the company, with a term beginning

effective January 1, 2018. It is anticipated that Mr. Waddill will serve

on the Audit, Compensation, and Nomination Committees.

Douglass Given, M.D., Ph.D., Chairman of the Board of Arrowhead said,

“Will is an accomplished biotechnology executive and board member and we

look forward to working with him during this exciting time for Arrowhead

as the company advances its pipeline of RNAi-therapeutics.”

William Waddill began his career 30 years ago in commercial banking and

public accounting and has been in the biotechnology industry for over 25

years. Currently, he is on the board of Protagonist Therapeutics and

most recently was Senior Vice President and CFO of Calithera Bioscience.

Prior to Calithera, Mr. Waddill was Senior Vice President and CFO at

OncoMed Pharmaceuticals from 2007 to 2014. Mr. Waddill served as the

Senior Vice President and CFO of Ilypsa, Inc., a biotechnology company

that was acquired in 2007 by Amgen, Inc. Before joining Ilypsa, he

served as the founder and principal at Square One Finance, a financial

consulting business, and Mr. Waddill served as Senior Director of

Finance and Administration at Exelixis, Inc., a biotechnology company.

Mr. Waddill received a BS in accounting from the University of Illinois,

Chicago, and certification as a public accountant (inactive) after

working at PriceWaterhouseCoopers and Deloitte in Boston.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable

diseases by silencing the genes that cause them. Using a broad portfolio

of RNA chemistries and efficient modes of delivery, Arrowhead therapies

trigger the RNA interference mechanism to induce rapid, deep, and

durable knockdown of target genes. RNA interference, or RNAi, is a

mechanism present in living cells that inhibits the expression of a

specific gene, thereby affecting the production of a specific protein.

Arrowhead’s RNAi-based therapeutics leverage this natural pathway of

gene silencing.

For more information, please visit www.arrowheadpharma.com,

or follow us on Twitter @ArrowheadPharma.

To be added to the Company’s email list and receive news directly,

please visit http://ir.arrowheadpharma.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform

Act:

This news release contains forward-looking statements within the

meaning of the “safe harbor” provisions of the Private Securities

Litigation Reform Act of 1995. These statements are based upon our

current expectations and speak only as of the date hereof. Our actual

results may differ materially and adversely from those expressed in any

forward-looking statements as a result of various factors and

uncertainties, including the safety and efficacy of our product

candidates, the duration and impact of regulatory delays in our clinical

programs, our ability to finance our operations, the future success of

our scientific studies, our ability to successfully develop drug

candidates, the timing for starting and completing clinical trials,

rapid technological change in our markets, and the enforcement of our

intellectual property rights. Our most recent Annual Report on Form 10-K

and subsequent Quarterly Reports on Form 10-Q discuss some of the

important risk factors that may affect our business, results of

operations and financial condition. We assume no obligation to update or

revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investors

and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com

Source: Arrowhead Pharmaceuticals, Inc.

News Provided by Acquire Media